JP7720148B2 - キメラ抗原受容体を発現する制御性ｔ細胞 - Google Patents

キメラ抗原受容体を発現する制御性ｔ細胞

Info

Publication number
JP7720148B2
JP7720148B2 JP2020539264A JP2020539264A JP7720148B2 JP 7720148 B2 JP7720148 B2 JP 7720148B2 JP 2020539264 A JP2020539264 A JP 2020539264A JP 2020539264 A JP2020539264 A JP 2020539264A JP 7720148 B2 JP7720148 B2 JP 7720148B2
Authority
JP
Japan
Prior art keywords
cells
antigen
car
treg
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020539264A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021511041A5 (enExample
JP2021511041A (ja
Inventor
ノバック，アンナ
ロック，ドミニク
カイザー，アンドリュー
シェフォルド，アレクサンダー
Original Assignee
ミルテニイ ビオテック ベー．ファー． ウント コー．カーゲー
シャリテ－ウニヴェルズィテートメディツィーン ベルリン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ミルテニイ ビオテック ベー．ファー． ウント コー．カーゲー, シャリテ－ウニヴェルズィテートメディツィーン ベルリン filed Critical ミルテニイ ビオテック ベー．ファー． ウント コー．カーゲー
Publication of JP2021511041A publication Critical patent/JP2021511041A/ja
Publication of JP2021511041A5 publication Critical patent/JP2021511041A5/ja
Application granted granted Critical
Publication of JP7720148B2 publication Critical patent/JP7720148B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/22—Intracellular domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2020539264A 2018-01-19 2019-01-17 キメラ抗原受容体を発現する制御性ｔ細胞 Active JP7720148B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18152631 2018-01-19
EP18152631.0 2018-01-19
PCT/EP2019/051143 WO2019141774A1 (en) 2018-01-19 2019-01-17 Regulatory t cell expressing a chimeric antigen receptor

Publications (3)

Publication Number Publication Date
JP2021511041A JP2021511041A (ja) 2021-05-06
JP2021511041A5 JP2021511041A5 (enExample) 2022-02-07
JP7720148B2 true JP7720148B2 (ja) 2025-08-07

Family

ID=61027458

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020539264A Active JP7720148B2 (ja) 2018-01-19 2019-01-17 キメラ抗原受容体を発現する制御性ｔ細胞

Country Status (8)

Country Link
US (1) US12178872B2 (enExample)
EP (1) EP3740569B1 (enExample)
JP (1) JP7720148B2 (enExample)
KR (1) KR102795692B1 (enExample)
CN (1) CN111684061B (enExample)
CA (1) CA3088832A1 (enExample)
ES (1) ES2960686T3 (enExample)
WO (1) WO2019141774A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111684061B (zh) 2018-01-19 2024-07-30 美天施生物科技有限两合公司 表达嵌合抗原受体的调节性t细胞
EP4013447A4 (en) * 2019-08-16 2024-05-29 H. Lee Moffitt Cancer Center & Research Institute, Inc. T CELLS EXPRESSING A CHIMERIC ANTI-CD83 ANTIGEN RECEPTOR
GB201912515D0 (en) * 2019-08-30 2019-10-16 King S College London Engineered regulatory T cell
CN115066249A (zh) * 2020-02-04 2022-09-16 美天施生物科技有限两合公司 表达用于感测可溶性抗原的适体嵌合抗原受体的免疫细胞
JP7791096B2 (ja) 2020-03-10 2025-12-23 セラレス コーポレーション 細胞処理のためのシステム、デバイス、及び方法
CA3259305A1 (en) * 2022-07-11 2024-01-18 Sonoma Biotherapeutics, Inc. RECOMBINANT CYTOKINE RECEPTORS AND METHODS OF USE
EP4683997A2 (en) 2023-03-21 2026-01-28 Cellares Corporation Systems, devices, and methods for electroporation within a cell processing system
US12399193B2 (en) 2023-05-05 2025-08-26 Cellares Corporation Systems, devices, and methods for combined cell processes
EP4467155A1 (en) * 2023-05-23 2024-11-27 Fundación para la Investigación Biomédica del Hospital Gregorio Marañón (FIBHGM) Car-thytreg cells, compositions and uses thereof in immunotherapy
EP4735577A2 (en) 2023-06-30 2026-05-06 Cellares Corporation Systems, devices, and methods for fluid transfer within an automated cell processing system
EP4766812A1 (en) 2023-08-21 2026-07-01 Cellares Corporation FLUID REGULATION SYSTEMS, DEVICES AND METHODS IN A CELL PROCESSING SYSTEM
US12337321B2 (en) 2023-08-21 2025-06-24 Cellares Corporation Systems, devices, and methods for automatic cell sorting
EP4766808A1 (en) 2023-08-21 2026-07-01 Cellares Corporation BIOREACTORS AND THEIR PROCESSES OF USE IN AUTOMATIC CELL PROCESSING SYSTEMS
US12492368B2 (en) 2024-03-11 2025-12-09 Cellares Corporation Monitoring air pressure within a cell processing system
WO2025202944A2 (en) 2024-03-27 2025-10-02 Cellares Corporation Liquid level and flow rate detection within a cell processing system
USD1109621S1 (en) 2024-04-15 2026-01-20 Cellares Corporation Analytical platform for biological material testing

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102153651B (zh) 2011-01-21 2012-11-14 厦门大学 抗葡聚糖单链抗体及其制备方法
US9523076B2 (en) 2009-09-10 2016-12-20 Miltenyi Biotec Gmbh Method for the identification and separation of non-regulatory T-cells from a mixture of regulatory T-cells
WO2017042170A1 (en) 2015-09-07 2017-03-16 INSERM (Institut National de la Santé et de la Recherche Médicale) A new subpopulation of cd8+cd45rclow tregs and uses thereof
WO2017075433A1 (en) 2015-10-30 2017-05-04 The Regents Of The University Of California Transforming growth factor-beta-responsive polypeptides and their methods for use
WO2017143094A1 (en) 2016-02-16 2017-08-24 Dana-Farber Cancer Institute, Inc. Immunotherapy compositions and methods
WO2017147383A1 (en) 2016-02-25 2017-08-31 Cell Medica Switzerland Ag Modified cells for immunotherapy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211118D0 (en) 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
GB0420466D0 (en) 2004-09-14 2004-10-20 Cassone Antonio Anti-glucan antibodies
EP2520643B8 (en) 2007-12-07 2019-11-27 Miltenyi Biotec B.V. & Co. KG Sample processing systems and methods
JP5897035B2 (ja) 2010-12-14 2016-03-30 ユニバーシティ オブ メリーランド，ボルチモア 汎用の抗タグキメラ抗原受容体発現ｔ細胞及びがんを治療する方法
CN122399016A (zh) * 2014-03-15 2026-07-17 诺华股份有限公司 使用嵌合抗原受体治疗癌症
PL3212225T3 (pl) 2014-10-31 2026-03-30 The Trustees Of The University Of Pennsylvania Sposoby i kompozycje zmodyfikowanych limfocytów t
CN109072194B (zh) 2015-12-09 2022-12-27 纪念斯隆-凯特林癌症中心 免疫细胞组合物及其使用方法
US20170274095A1 (en) * 2016-03-23 2017-09-28 The Board Of Trustees Of The Leland Stanford Junior University Enhanced regulatory t cells targeted to sites of inflammation with chimeric antigen receptors and expressing factors that enhance viability of pancreatic cells
US10617720B2 (en) * 2016-10-20 2020-04-14 Miltenyi Biotech, GmbH Chimeric antigen receptor specific for tumor cells
EP3336107A1 (en) * 2016-12-15 2018-06-20 Miltenyi Biotec GmbH Immune cells expressing an antigen binding receptor and a chimeric costimulatory receptor
CN107557342A (zh) 2017-11-02 2018-01-09 广东万海细胞生物科技有限公司 一种CAR‑Treg 细胞的制备方法及其应用
CN111684061B (zh) 2018-01-19 2024-07-30 美天施生物科技有限两合公司 表达嵌合抗原受体的调节性t细胞
CN117693439A (zh) 2021-07-28 2024-03-12 伊顿智能动力有限公司 自适应可控车辆逆变器系统和方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9523076B2 (en) 2009-09-10 2016-12-20 Miltenyi Biotec Gmbh Method for the identification and separation of non-regulatory T-cells from a mixture of regulatory T-cells
CN102153651B (zh) 2011-01-21 2012-11-14 厦门大学 抗葡聚糖单链抗体及其制备方法
WO2017042170A1 (en) 2015-09-07 2017-03-16 INSERM (Institut National de la Santé et de la Recherche Médicale) A new subpopulation of cd8+cd45rclow tregs and uses thereof
WO2017075433A1 (en) 2015-10-30 2017-05-04 The Regents Of The University Of California Transforming growth factor-beta-responsive polypeptides and their methods for use
WO2017143094A1 (en) 2016-02-16 2017-08-24 Dana-Farber Cancer Institute, Inc. Immunotherapy compositions and methods
WO2017147383A1 (en) 2016-02-25 2017-08-31 Cell Medica Switzerland Ag Modified cells for immunotherapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BSGCT annual conference, 2014年, p.A20(P042)

Also Published As

Publication number Publication date
KR102795692B1 (ko) 2025-04-16
WO2019141774A1 (en) 2019-07-25
CN111684061A (zh) 2020-09-18
US20200353004A1 (en) 2020-11-12
ES2960686T3 (es) 2024-03-06
EP3740569A1 (en) 2020-11-25
EP3740569B1 (en) 2023-07-26
JP2021511041A (ja) 2021-05-06
KR20200113211A (ko) 2020-10-06
US12178872B2 (en) 2024-12-31
CN111684061B (zh) 2024-07-30
CA3088832A1 (en) 2019-07-25

Similar Documents

Publication Publication Date Title
CN111684061B (zh) 表达嵌合抗原受体的调节性t细胞
US20220281944A1 (en) Spycatcher and spytag: universal immune receptors for t cells
US12234274B2 (en) Use of the CD2 signaling domain in second-generation chimeric antigen receptors
JP2023029373A (ja) キメラ抗体受容体（ＣＡＲｓ）の組成物およびその使用方法
US20190330300A1 (en) Universal Immune Receptor Expressed by T Cells for the Targeting of Diverse and Multiple Antigens
JP2018515123A (ja) 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
CA3098865A1 (en) Compositions and methods of phospholipase a2 receptor chimeric autoantibody receptor t cells
JP2021532742A (ja) Ｎｅｆを含むｔ細胞及びその生成方法
US12473342B2 (en) Chimeric antigen receptor T regulatory cells for the treatment of atherosclerosis
JP2021526795A (ja) 筋特異的キナーゼキメラ自己受容体細胞の組成物および方法
WO2021046205A1 (en) Adoptive cell therapy and methods of dosing thereof
WO2021151038A1 (en) Quantitative control of activity of engineered cells expressing universal immune receptors
US12258379B2 (en) Compositions and methods for switchable CAR T cells using surface-bound sortase transpeptidase

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220111

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230330

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230606

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7421

Effective date: 20250512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250512

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250728

R150 Certificate of patent or registration of utility model

Ref document number: 7720148

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150